Toronto, Canada

David Zi Cherney

USPTO Granted Patents = 2 

Average Co-Inventor Count = 9.6

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: David Zi Cherney: Innovator in Pharmaceutical Composition

Introduction

David Zi Cherney is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for diabetes and related cardiovascular conditions. With a total of 2 patents, his work is recognized for its potential impact on patient care.

Latest Patents

Cherney's latest patents focus on pharmaceutical compositions and methods for treating various health conditions. One of his inventions involves certain SGLT-2 inhibitors aimed at treating and preventing oxidative stress in patients with type 1 or type 2 diabetes. This invention also addresses the use of these inhibitors in the treatment and prevention of cardiovascular diseases. Another patent relates to the use of SGLT-2 inhibitors for treating chronic kidney disease in patients, including those with prediabetes and diabetes mellitus.

Career Highlights

David Zi Cherney is currently associated with Boehringer Ingelheim International GmbH, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to improving health outcomes for patients suffering from chronic conditions.

Collaborations

Cherney has collaborated with esteemed colleagues such as Uli Christian Broedl and Odd-Erik Johansen. These partnerships have further enhanced the quality and reach of his research and inventions.

Conclusion

David Zi Cherney stands out as a significant figure in the pharmaceutical industry, with his inventions poised to make a meaningful difference in the treatment of diabetes and related diseases. His contributions reflect a dedication to advancing medical science and improving patient health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…